Toggle Main Menu Toggle Search

Open Access padlockePrints

European multicenter study on propionyl-L-carnitine in intermittent claudication

Lookup NU author(s): David Lambert


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


OBJECTIVES This study was performed to identify a target population of claudicants for propionyl-L-carnitine treatment. BACKGROUND Previous studies suggest that the efficacy of propionyl-L-carnitine in intermittent claudication is greater in patients with severe functional impairment than in those with mild walking disability. METHODS After run-in, 485 claudicant patients were randomized to placebo or propionyl-L-carnitine (1 g bid, po) and then stratified on the basis of maximal walking distance (cutoff point 250 m) and maximal walking distance variability (cutoff Feint 25%). Treatment lasted 12 months. Walking capacity was assessed by treadmill and quality of life by a questionnaire exploring various aspects of daily life. RESULTS In the target population, that is, patients who at baseline walked less than or equal to 250 m and showed a maximal walking distance variability less than or equal to 25%, per-protocol analysis showed that the effect of propinyl-L-carnitine was significantly greater than that with placebo for both maximal walking distance and initial claudication distance (ICD). In the intention-to-treat population, maximal walking distance increased by 62 +/- 14% on propionyl-L-carnitine and by 46 +/- 9% (p < 0.05) on placebo, while no difference between treatments was observed for ICD. The beneficial effect of propionyl-L-carnitine mas confirmed when data of the target population were pooled with these of patients who at baseline walked less than or equal to 250 m and showed a >25% maximal walking distance <50% variability. Actually, maximal walking distance increased by 98 +/- 16% in the propionyl-L-carnitine group and by only 54 +/- 10% in the placebo group (p < 0.01). The corresponding values for ICD were 99 +/- 21% and 51 +/- 8% (p < 0.05). For patients with baseline maximal walking distance >250 m, no difference between treatments was observed. CONCLUSIONS Claudicants with maximal walking distance less than or equal to 250 m benefited from the use of propionyl-L-carnitine, with improvement in walking distance and quality of life. However, patients with mild functional impairment (i.e., walking distance >250 m) showed no response to propionyl-L-carnitine. (C) 1999 by the American College of Cardiology.

Publication metadata

Author(s): Brevetti G, Diehm C, Lambert D, Study Investigators

Publication type: Article

Publication status: Published

Journal: Journal of the American College of Cardiology

Year: 1999

Volume: 34

Issue: 5

Pages: 1618-1624

Print publication date: 29/10/1999

ISSN (print):

ISSN (electronic): 1558-3597

Publisher: Elsevier Inc.


DOI: 10.1016/S0735-1097(99)00373-3


Altmetrics provided by Altmetric